相关实验视频

Updated: May 17, 2025

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

在T细胞中准Setdb1可以诱导移植耐受性,而不会损害抗瘤免疫力

Xiaosheng Tan^1,2, Xiangli Zhao¹, Zunsong Hu^3,4

¹Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430030, Wuhan, People's Republic of China.

Nature communications

|May 15, 2025

概括

抑制T细胞中的Setdb1通过增加调节性T (Treg) 细胞,同时保持抗瘤免疫力,促进全移植生存. 这将免疫抑制与瘤保护分开.

科学领域:

免疫学免疫学免疫学
表观遗传学在表观遗传学中,表观遗传学是指表观遗传学.
移植生物学移植生物学

背景情况:

抑制免疫反应有助于全移植的生存,但可以促进瘤的生长.
一个挑战在于选择性地抑制异体移植排斥,同时保持抗瘤免疫力.

研究的目的:

调查Setdb1 (一种H3K9甲基转移酶) 在调节移植生存和抗瘤免疫的免疫反应中的作用.
阐明Setdb1影响T调控 (Treg) 细胞分化和功能的机制.

主要方法:

使用了缺少Setdb1.1的小鼠.
进行RNA测序和单细胞RNA测序.
枯竭的调节性T细胞,以评估它们在移植接受中的作用.

主要成果:

由于Setdb1的缺陷导致了异种移植体排斥的丧失,而不会影响抗瘤免疫力.
缺乏setdb1的小鼠表现出Treg细胞相关基因表达的增加.
Setdb1 缺陷诱导了胸腺中一种新的Treg细胞群,改变了IL-1R2和IL-18R1的表达.
在Treg细胞分化过程中,Setdb1在Foxp3诱导的上游运行.

结论:

在T细胞中的Setdb1作为Treg细胞分化的关键调节者.
在T细胞中丧失Setdb1功能将异位移植排斥抑制与抗瘤免疫维护分离.
向Setdb1可能提供一种改善移植结果的策略,而不会增加癌症风险.

更多相关视频

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

相关概念视频

Cell-mediated Immune Responses

Cell-mediated Immune Responses

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.